Brimonidine L-tartrate

Modify Date: 2024-01-02 17:51:07

Brimonidine L-tartrate structure	Common Name	Brimonidine L-tartrate
	CAS Number	70359-46-5	Molecular Weight	442.221
	Density	N/A	Boiling Point	432.6ºC at 760 mmHg
	Molecular Formula	C₁₅H₁₆BrN₅O₆	Melting Point	207-208ºC (dec.)
	MSDS	N/A	Flash Point	215.4ºC
	Symbol	GHS06	Signal Word	Danger

Use of Brimonidine L-tartrate

UK 14,304 is a full α2-adrenergic receptor (α2-AR) agonist.Target: α2-adrenergic Receptor[3H]UK 14,034 is a full agonist at alpha 2-adrenergic receptors. [3H]UK 14,304 labels at least 2 specific binding sites in human brain that both have the characteristics of an alpha 2-adrenergic binding site. GTP decreases agonist binding at both of these sites, but with different potencies at each site [1-3].

Name	5-Bromo-N-(4,5-Dihydro-1H-Imidazol-2-yl)-6-Quinoxalinamine Tartrate
Synonym	More Synonyms

Description	UK 14,304 is a full α2-adrenergic receptor (α2-AR) agonist.Target: α2-adrenergic Receptor[3H]UK 14,034 is a full agonist at alpha 2-adrenergic receptors. [3H]UK 14,304 labels at least 2 specific binding sites in human brain that both have the characteristics of an alpha 2-adrenergic binding site. GTP decreases agonist binding at both of these sites, but with different potencies at each site [1-3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Others
References	[1]. Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43(22): p. 1805-12. [2]. Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5. [3]. Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288(2): p. 798-804.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor

Research Areas >> Others

References

[1]. Andorn, A.C., M.A. Carlson, and R.C. Gilkeson, Specific [3H]UK 14,304 binding in human cortex occurs at multiple high affinity states with alpha 2-adrenergic selectivity and differing affinities for GTP. Life Sci, 1988. 43(22): p. 1805-12.

[2]. Cambridge, D., UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol, 1981. 72(4): p. 413-5.

[3]. Chopin, P., F.C. Colpaert, and M. Marien, Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther, 1999. 288(2): p. 798-804.

Boiling Point	432.6ºC at 760 mmHg
Melting Point	207-208ºC (dec.)
Molecular Formula	C₁₅H₁₆BrN₅O₆
Molecular Weight	442.221
Flash Point	215.4ºC
Exact Mass	441.028381
PSA	177.26000
Storage condition	-20°C Freezer

Material Safety Data Sheet

Section1. Identiﬁcation of the substance
Product Name: Brimonidine L-Tartrate
Synonyms:Brimonidine Tartrate

Section2. Hazards identiﬁcation
Harmful by inhalation, in contact with skin, and if swallowed.

Section3. Composition/information on ingredients.
Ingredient name:Brimonidine L-Tartrate
CAS number:70359-46-5

Section4. First aid measures
Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
ﬂushing of the eyes by separating the eyelids with ﬁngers. If irritation persists, seek medical
attention.
Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section5. Fire ﬁghting measures
In the event of a ﬁre involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution:Wear approved mask/respirator
Hand precaution:Wear suitable gloves/gauntlets
Skin protection:Wear suitable protective clothing
Eye protection:Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section7. Handling and storage
Handling:This product should be handled only by, or under the close supervision of, those properly qualiﬁed
in the handling and use of potentially hazardous chemicals, who should take into account the ﬁre,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section9. Physical and chemical properties
Appearance:Not speciﬁed
Boiling point:No data
No data
Melting point:
Flash point:No data
Density:No data
Molecular formula:C15H16BrN5O6
Molecular weight:442.2

Section10. Stability and reactivity
Conditions to avoid: Heat, ﬂames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section11. Toxicological information
No data.

Section12. Ecological information
No data.

Section13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section14. Transportation information
Non-harzardous for air and ground transportation.

Section15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

SECTION 16 - ADDITIONAL INFORMATION
N/A

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301-H315-H319-H335
Precautionary Statements	Missing Phrase - N15.00950417-P305 + P351 + P338
Safety Phrases	S36/37
RIDADR	UN 2811 6.1 / PGIII
HS Code	2933990090

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK.

J. Refract. Surg. 29(7) , 469-75, (2013)

To investigate whether dilute brimonidine (0.025%) reduces patient discomfort, subconjunctival hemorrhage, and injection after LASIK without a significant increase in the rate of flap complications or...

Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.

Invest. Ophthalmol. Vis. Sci. 55(11) , 7387-97, (2014)

In this work, we tested the hypothesis that highly targeted delivery of antiglaucoma drugs to the supraciliary space by using a hollow microneedle allows dramatic dose sparing of the drug compared to ...

Determinants and characteristics of angle-closure disease in an elderly Chinese population.

Ophthalmic Epidemiol. 22(2) , 109-15, (2015)

To determine factors associated with angle-closure disease, particularly in those with structural or functional damage to the eyes, in an elderly Chinese population.A total of 460 individuals aged ove...

Brimonidine tartrate

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl) quinoxalin-6-amine tartrate

(2R,3R)-2,3-Dihydroxysuccinic acid - 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (1:1)

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-tartrate

5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine, (2R,3R)-2,3-dihydroxybutanedioate

Butanedioic acid, 2,3-dihydroxy-, (2R,3R)-, compd. with 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (1:1)

MFCD07773086

UK 14,304 (tartrate)